Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial.
Saved in:
| Title: | Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial. |
|---|---|
| Authors: | Severe P; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Pierre S; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Homeus F; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Marc JB; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Trevisi L; Harvard Medical School, Boston, MA, USA., Aristhomene ML; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Bernadin GR; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Lavoile K; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Rivera V; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Duchatellier CF; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Joseph MJ; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Wu J; Analysis Group Inc, Boston, MA, USA., Rouzier V; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti; Weill Cornell Medical College, New York, NY, USA., Preval F; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Jean E; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Bernadin J; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Zion A; Analysis Group Inc, Boston, MA, USA., Pierre Louis Forestal G; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Avila-Rios S; Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico., Garcia Morales C; Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico., Zhang A; Analysis Group Inc, Boston, MA, USA., Israelski D; Gilead Sciences, Foster City, CA, USA., Apollon A; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Dumont E; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Fox E; Cornell University, Ithaca, NY, USA., Cremieux PY; Analysis Group Inc, Boston, MA, USA., Pape JW; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti; Weill Cornell Medical College, New York, NY, USA., Collins SE; Gilead Sciences, Foster City, CA, USA., Liautaud B; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Sax PE; Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA., Koenig SP; Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address: skoenig@bwh.harvard.edu. |
| Source: | The lancet. HIV [Lancet HIV] 2025 Sep; Vol. 12 (9), pp. e616-e626. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Equivalence Trial |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40883049 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Severe+P%22">Severe P</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Pierre+S%22">Pierre S</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Homeus+F%22">Homeus F</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Marc+JB%22">Marc JB</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Trevisi+L%22">Trevisi L</searchLink>; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Aristhomene+ML%22">Aristhomene ML</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Bernadin+GR%22">Bernadin GR</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Lavoile+K%22">Lavoile K</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Rivera+V%22">Rivera V</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Duchatellier+CF%22">Duchatellier CF</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Joseph+MJ%22">Joseph MJ</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Wu+J%22">Wu J</searchLink>; Analysis Group Inc, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Rouzier+V%22">Rouzier V</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti; Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Preval+F%22">Preval F</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Jean+E%22">Jean E</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Bernadin+J%22">Bernadin J</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Zion+A%22">Zion A</searchLink>; Analysis Group Inc, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pierre+Louis+Forestal+G%22">Pierre Louis Forestal G</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Avila-Rios+S%22">Avila-Rios S</searchLink>; Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.<br /><searchLink fieldCode="AU" term="%22Garcia+Morales+C%22">Garcia Morales C</searchLink>; Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.<br /><searchLink fieldCode="AU" term="%22Zhang+A%22">Zhang A</searchLink>; Analysis Group Inc, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Israelski+D%22">Israelski D</searchLink>; Gilead Sciences, Foster City, CA, USA.<br /><searchLink fieldCode="AU" term="%22Apollon+A%22">Apollon A</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Dumont+E%22">Dumont E</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Fox+E%22">Fox E</searchLink>; Cornell University, Ithaca, NY, USA.<br /><searchLink fieldCode="AU" term="%22Cremieux+PY%22">Cremieux PY</searchLink>; Analysis Group Inc, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pape+JW%22">Pape JW</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti; Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Collins+SE%22">Collins SE</searchLink>; Gilead Sciences, Foster City, CA, USA.<br /><searchLink fieldCode="AU" term="%22Liautaud+B%22">Liautaud B</searchLink>; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.<br /><searchLink fieldCode="AU" term="%22Sax+PE%22">Sax PE</searchLink>; Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Koenig+SP%22">Koenig SP</searchLink>; Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address: skoenig@bwh.harvard.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101645355%22">The lancet. HIV</searchLink> [Lancet HIV] 2025 Sep; Vol. 12 (9), pp. e616-e626. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Equivalence Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+B%2EV%22">Elsevier B.V </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101645355 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3018 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523018%22">23523018 </searchLink><i>NLM ISO Abbreviation: </i>Lancet HIV <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40883049 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2352-3018(25)00130-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e616 Titles: – TitleFull: Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Severe P – PersonEntity: Name: NameFull: Pierre S – PersonEntity: Name: NameFull: Homeus F – PersonEntity: Name: NameFull: Marc JB – PersonEntity: Name: NameFull: Trevisi L – PersonEntity: Name: NameFull: Aristhomene ML – PersonEntity: Name: NameFull: Bernadin GR – PersonEntity: Name: NameFull: Lavoile K – PersonEntity: Name: NameFull: Rivera V – PersonEntity: Name: NameFull: Duchatellier CF – PersonEntity: Name: NameFull: Joseph MJ – PersonEntity: Name: NameFull: Wu J – PersonEntity: Name: NameFull: Rouzier V – PersonEntity: Name: NameFull: Preval F – PersonEntity: Name: NameFull: Jean E – PersonEntity: Name: NameFull: Bernadin J – PersonEntity: Name: NameFull: Zion A – PersonEntity: Name: NameFull: Pierre Louis Forestal G – PersonEntity: Name: NameFull: Avila-Rios S – PersonEntity: Name: NameFull: Garcia Morales C – PersonEntity: Name: NameFull: Zhang A – PersonEntity: Name: NameFull: Israelski D – PersonEntity: Name: NameFull: Apollon A – PersonEntity: Name: NameFull: Dumont E – PersonEntity: Name: NameFull: Fox E – PersonEntity: Name: NameFull: Cremieux PY – PersonEntity: Name: NameFull: Pape JW – PersonEntity: Name: NameFull: Collins SE – PersonEntity: Name: NameFull: Liautaud B – PersonEntity: Name: NameFull: Sax PE – PersonEntity: Name: NameFull: Koenig SP IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2025 Sep Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2352-3018 Numbering: – Type: volume Value: 12 – Type: issue Value: 9 Titles: – TitleFull: The lancet. HIV Type: main |
| ResultId | 1 |
